🇮🇳 Zydus Lifesciences Ltd

Press Release 06-11-2026 18:57:36 IST

Overview: Zydus Therapeutics reported Phase 2b trial results for saroglitazar magnesium, showing 39.1% and 32.4% resolution of steatohepatitis in MASH patients versus 13.7% for placebo.

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest